Informatics Publishing Limited

K. S. Negi ¹, S. S. Koranga ¹, S. N. Ojha ¹, M. M. Pandey ¹, A. K. S. Rawat ¹, A. P. Raina ¹, A. Rayal ¹

Affiliations
1 National Bureau of Plant Genetic Resources, Bhowali-263 132, Niglat, Nainital, Uttarakhand

Abstract

Spiked Zinger Lily, a perennial rhizomatous herb, belongs to family Zingiberaceae, commonly known as 'Kapur-kachari' widely available in moist, damp-shady evergreen forests and popular in traditional systems with several ethnobotanical notes. For identification of superior genotypes, a total of 34 accessions were collected from Indian Himalayan Region along with passport information. Rhizomes of all accessions were chopped, dried and subjected to Clevenger Hydro-distillation unit for essential oil extraction and observed 0.06-6.12% oil yield. In addition to this 1, 8 cineole (8.22 -58.15 %) was observed as a major constituent of the essential oils on Gas Chromatography (GC). Essential oil content and major chemical constituent 1, 8 cineole, both the parameters revealed an increasing trend along an altitudinal gradient of 1400-2875 m amsl.

Keywords

Hedychium Spicatum, Indian Himalayan Region, Essential Oil, 1, 8 Cineole, Superior Genotypes, Altitudinal Gradient.

Full Text

     

Brahma N. Singh ¹, Prateeksha ¹, Ch. V. Rao ¹, A. K. S. Rawat ¹, Dalip K. Upreti ¹, Braj R. Singh ²

Affiliations
1 Pharmacognosy and Ethnopharmacology Division, CSIR-National Botanical Research Institute, Lucknow 226 001, IN
2 Centre of Excellence in Materials Science (Nanomaterials), Z.H. College of Engineering and Technology, Aligarh Muslim University, Aligarh 202 002, IN

Abstract

The current challenges of multi-drug resistance development in human pathogenic microorganisms are engaging researchers in exploring the field of nanotechnology-derived approaches and products as new tools of key developments for manufacturing effective antimicrobials. But, the real contributions are still uncertain. Although there are several budding leads of nanotechnology and the growing trends in publications and patents, therapeutic microbiological applications have not yet made it to the market. Numerous reasons could explain the scarcity of commercial applications. These include high initial production investments, new nanotechnology regulation in the developed and developing countries, and public perception. The rapid progress of nanotechnology in other key areas may over time be transferred to therapeutic microbiological applications as well, and accelerate their development.

Full Text